AGT-181

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
19	ライソゾーム病	4

19. ライソゾーム病

臨床試験数 : 899 / 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182

trials per page:

Showing 1 to 4 of 4 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03071341 (ClinicalTrials.gov)	October 2016	27/2/2017	Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I	An Extension Study Evaluating Long Term Safety and Activity of AGT-181in Patients With Mucopolysacch ...	Mucopolysaccharidosis I	Drug: AGT-181	ArmaGen, Inc	NULL	Completed	2 Years	N/A	All	19	Phase 1/Phase 2	Brazil
2	NCT02597114 (ClinicalTrials.gov)	November 2015	3/11/2015	Extension Study of AGT-181-102 to Evaluate Long Term Safety and Activity of AGT-181	An Extension Study of AGT-181-102 Evaluating Safety and Glycosaminoglycans (GAGs) in Adult Patients ...	Mucopolysaccharidosis I	Drug: AGT-181	ArmaGen, Inc	NULL	Completed	18 Years	N/A	All	3	Phase 1	NULL
3	NCT03053089 (ClinicalTrials.gov)	October 2015	9/2/2017	Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Childr ...	A Two-Stage, Phase 1/2, Open-Label Study of the Human Insulin Receptor Monoclonal Antibody-Human Alp ...	Mucopolysaccharidosis I	Drug: AGT-181	ArmaGen, Inc	NULL	Completed	2 Years	N/A	All	21	Phase 1/Phase 2	Brazil
4	NCT02371226 (ClinicalTrials.gov)	July 2015	19/2/2015	Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I	A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha- ...	Mucopolysaccharidosis I	Drug: AGT-181 (HIRMAb-IDUA)	ArmaGen, Inc	NULL	Completed	18 Years	N/A	All	3	Phase 1	United States

First Previous1Next Last